Masimo Corporation
MASI
Rank in Stocks
#2165
Masimo Corporation engages in the development, manufacture, and marketing of... Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Share Price
$179.95
Last synced: 2026-06-12
Market Cap
$9.42B
Change (1 day)
0.00%
Change (1 year)
22.41%
Country
US
Trade Masimo Corporation (MASI)
Category
Healthcare
P/E ratio for Masimo Corporation (MASI)
P/E ratio as of October 2026 TTM: 124.97
According to Masimo Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 124.97. At the end of 2023 the company had a P/E ratio of 75.93.
P/E ratio history for Masimo Corporation from 2002 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 124.97 | -518.08% |
| 2024 | -29.89 | -139.36% |
| 2023 | 75.93 | 37.41% |
| 2022 | 55.26 | -9.54% |
| 2021 | 61.09 | 40.66% |
| 2019 | 43.43 | 42.10% |
| 2018 | 30.56 | -7.92% |
| 2017 | 33.19 | 198.94% |
| 2016 | 11.10 | -43.13% |
| 2015 | 19.52 | -30.33% |
| 2013 | 28.02 | 47.61% |
| 2012 | 18.98 | 8.49% |
| 2011 | 17.50 | -46.84% |
| 2010 | 32.92 | -37.17% |
| 2009 | 52.39 | 0.00% |
| 2007 | 52.39 | 2,696.07% |
| 2006 | 1.87 | -91.23% |
| 2005 | 21.37 | -111.51% |
| 2004 | -185.66 | 79.39% |
| 2003 | -103.49 | -97.36% |
| 2002 | -3.92K | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 33.11 | -73.51% |
US
|
|
| 21.39 | -82.89% |
IE
|
|
| 28.94 | -76.84% |
US
|
|
| 17.34 | -86.13% |
US
|
|
| - | - |
DE
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.